Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Intradialytic Parenteral Nutrition (IDPN) by Fresenius Kabi is a specialized nutritional support therapy administered to malnourished patients undergoing chronic hemodialysis. The therapy involves the intravenous infusion of a concentrated mixture of amino acids, carbohydrates (typically dextrose), and lipid emulsions directly into the venous drip chamber of the dialysis circuit during treatment sessions. This approach is designed to supplement the patient's oral or enteral intake, bypassing gastrointestinal absorption limitations and addressing protein-energy wasting (PEW), which is a significant contributor to morbidity and mortality in end-stage renal disease (ESRD). Fresenius Kabi provides both standardized multi-chamber bags and tailored compounded solutions containing essential macronutrients, vitamins, and trace elements specifically formulated for the metabolic needs of renal patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Intradialytic Parenteral Nutrition.